MRK · 10-Q · 2026Q3 · Full report
LIPFENDRA Product Launch
Merck & Co., Inc. · 2026-11-04 · Importance 41 · Surprise 60 · In source text
Merck announced FDA approval of Lipfendra tablets in July 2026 as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. Lipfendra is a novel macrocyclic peptide and the first FDA-approved oral PCSK9 inhibitor shown to lower LDL-C. Its approval was based on the CORALreef Lipids and CORALreef HeFH clinical trials. The filing describes the product’s approval and mechanism but does not provide launch sales or uptake data in this section.
Key facts
- FDA approved Lipfendra tablets in July 2026 as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH. source
- Lipfendra (MK-0616) is under review in the EU for adults with primary hypercholesterolemia or mixed dyslipidemia, and in Japan for hypercholesterolemia and familial hypercholesterolemia, as well as in China. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | FDA approved Lipfendra tablets in July 2026 as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia,… |